ArticleFrontiers in oncology2023

Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study.

Paolo A Ascierto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.